Francesca Catto

Aug 17, 2024 | biorxiv.org | Ehsan Dadgar-Kiani |Daniel Kirschenbaum |Athena Economides |Francesca Catto

AbstractA hallmark of Alzheimer's disease (AD) is the extracellular aggregation of toxic amyloid-beta (Aβ) peptides in form of plaques. Here, we identify netoglitazone, an antidiabetic compound previously tested in humans, as an Aβ aggregation antagonist. Netoglitazone improved cognition and reduced microglia activity in a mouse model of AD.